MBX-500

structure in first source

Networked: 2 relevant articles (2 outcomes, 0 trials/studies)

1.	Weight Gain 09/01/2012 - "Finally, MBX-500 was efficacious in a murine model of CDI, again demonstrating a fully protective effect and permitting near-normal weight gain in the treated animals. " 09/01/2012 - "Hamsters treated with MBX-500 displayed significantly greater weight gain than did those treated with vancomycin. "
2.	Infections 09/01/2012 - "MBX-500 was active in acute and recurrent infections in a toxigenic hamster model of CDI, exhibiting full protection against acute infections and prevention of recurrence in 70% of the animals. "
3.	Clostridium Infections 08/01/2013 - "MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets." 08/01/2013 - "The novel antibiotic MBX-500, dosed at 100, 200, or 400 mg/kg twice daily for 7 days, was evaluated for the treatment of Clostridium difficile infection (CDI) in the gnotobiotic pig model. "
4.	Reinfection 09/01/2012 - "MBX-500 was active in acute and recurrent infections in a toxigenic hamster model of CDI, exhibiting full protection against acute infections and prevention of recurrence in 70% of the animals. "
5.	Diarrhea 08/01/2013 - "Our results show that MBX-500 is an effective antibiotic for the treatment of diarrhea associated with CDI and prevents severe systemic disease. "

1.	Vancomycin
2.	Anti-Bacterial Agents (Antibiotics)